stoxline Quote Chart Rank Option Currency Glossary
  
Incyte Corporation (INCY)
104.805  1.375 (1.33%)    01-14 11:19
Open: 103.66
High: 105.1
Volume: 308,958
  
Pre. Close: 103.43
Low: 103.198
Market Cap: 20,576(M)
Technical analysis
2026-01-14 10:46:44 AM
Short term     
Mid term     
Targets 6-month :  131.15 1-year :  153.18
Resists First :  112.29 Second :  131.15
Pivot price 103.03
Supports First :  100.7 Second :  93.54
MAs MA(5) :  105.32 MA(20) :  102.04
MA(100) :  94.29 MA(250) :  78.66
MACD MACD :  1.6 Signal :  1.3
%K %D K(14,3) :  47.8 D(3) :  54.5
RSI RSI(14): 54
52-week High :  112.29 Low :  53.56
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ INCY ] has closed below upper band by 42.5%. Bollinger Bands are 31.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 107.67 - 108.34 108.34 - 108.82
Low: 101.11 - 101.93 101.93 - 102.51
Close: 102.35 - 103.55 103.55 - 104.4
Company Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Headline News

Wed, 14 Jan 2026
Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance

Tue, 13 Jan 2026
Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus

Mon, 12 Jan 2026
How Positive frontMIND Phase 3 DLBCL Data May Reshape Incyte’s (INCY) Oncology Pipeline Story - simplywall.st

Mon, 12 Jan 2026
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative

Mon, 12 Jan 2026
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz

Mon, 12 Jan 2026
INCY: Diversified pipeline and disciplined investment aim to drive top-tier growth post-Jakafi - TradingView — Track All Markets

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 196 (M)
Shares Float 164 (M)
Held by Insiders 1.9 (%)
Held by Institutions 105.6 (%)
Shares Short 10,750 (K)
Shares Short P.Month 9,500 (K)
Stock Financials
EPS 5.9
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 23.71
Profit Margin 24.7 %
Operating Margin 31.6 %
Return on Assets (ttm) 13.5 %
Return on Equity (ttm) 30.3 %
Qtrly Rev. Growth 20 %
Gross Profit (p.s.) 13.85
Sales Per Share 24.5
EBITDA (p.s.) 6.72
Qtrly Earnings Growth 290.7 %
Operating Cash Flow 1,250 (M)
Levered Free Cash Flow 531 (M)
Stock Valuations
PE Ratio 17.63
PEG Ratio 0
Price to Book value 4.38
Price to Sales 4.24
Price to Cash Flow 16.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android